Delivered-To: tjphuhs@gmail.com Received: by 2002:a5d:6502:0:b0:439:fcfb:30e with SMTP id x2csp641778wru; Wed, 25 Mar 2026 08:55:43 -0700 (PDT) X-Received: by 2002:a17:90b:3dc6:b0:358:f0d0:1a19 with SMTP id 98e67ed59e1d1-35c0dca8bc3mr4072746a91.12.1774454142861; Wed, 25 Mar 2026 08:55:42 -0700 (PDT) ARC-Seal: i=1; a=rsa-sha256; t=1774454142; cv=none; d=google.com; s=arc-20240605; b=KGkLcVxB2q8RE9TZZxQkM6OIJLw9LRMAgz/iJHi6PLaFTeUfCE9/me3XLselRVSQTJ kSjwQ8RxImhb+W0tXWwhUkG4VYaq/7mc9XsJx207peW1r5eZqRabhzMBLj5xW0hDLK5g 2os3wCyogou9KB6zLtH0FS6mh+E8KZZ3a+AjYC42h+fIMP5mQu3uxmPYYug0ADzOc4cm jRWGXU3ph3bXNw7qXFH1gdSR/N6zJUKxi+1DdmfIxCAxZbeT2damsxfPnyqlrNHtvyeC YQ40Fq1sJ5CMn/gs5otr/uZEkiUwpa8jRbuN26dp/Bcx6FwnaVlKxruJhmWNklyzAQ2d +8ag== ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20240605; h=list-unsubscribe-post:list-unsubscribe:list-post:list-id :list-archive:list-url:list-owner:reply-to:in-reply-to:references :sender:feedback-id:date:message-id:to:from:subject:mime-version :dkim-signature:dkim-signature; bh=qNEgRmigRbz4VRYpf4dnZkeJfIF14ZBEw3GW25uocU8=; fh=9zP21OW67FFZD2VV42mGudo540Qp4aalMWxJB5kMYug=; b=AqAilRKVoR4B2rZ8aDQNQOuVnSOXwM3Aptaqx8wdyF/ke83zg+kmIgtyQDeMSibISw Uh5T6pZonAmhiOlE4dOpfPTl3aAn7nK3CwmZNI5DcxJcmFYJzamojIVVIj1P5vW6xVm5 VQ0SLVbjyJPR1xRFWLmJw27jOpOhJFSDLdTX3OKlzDkuoCf4y62mJcwMcg8iXyDrLkt5 ZwvHzYQmCAqk3ZWBemEmxm0WDc3YNKiU3iAby8lvmfSqw1IALudqutXcdTXFMkyGVDtA zz+DQsT4Q8sTos6DzS+RjBITKqb35ZZxRENnU3O1NWVitK81VZgiFotp6ahAt+7a483J 6Dkg==; dara=google.com ARC-Authentication-Results: i=1; mx.google.com; dkim=pass header.i=@mg2.substack.com header.s=mailo header.b=j+s1h3F5; dkim=pass header.i=@mailgun.org header.s=mg header.b=L2fiHnCn; spf=pass (google.com: domain of bounce+a6cce7.4d1858-tjphuhs=gmail.com@mg2.substack.com designates 161.38.201.183 as permitted sender) smtp.mailfrom="bounce+a6cce7.4d1858-tjphuhs=gmail.com@mg2.substack.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=substack.com Return-Path: Received: from v5183.v5075e2e3.usw1.send.mailgun.net (v5183.v5075e2e3.usw1.send.mailgun.net. [161.38.201.183]) by mx.google.com with UTF8SMTPS id 98e67ed59e1d1-35c1a031093si789936a91.2.2026.03.25.08.55.42 for (version=TLS1_2 cipher=ECDHE-ECDSA-AES128-GCM-SHA256 bits=128/128); Wed, 25 Mar 2026 08:55:42 -0700 (PDT) Received-SPF: pass (google.com: domain of bounce+a6cce7.4d1858-tjphuhs=gmail.com@mg2.substack.com designates 161.38.201.183 as permitted sender) client-ip=161.38.201.183; Authentication-Results: mx.google.com; dkim=pass header.i=@mg2.substack.com header.s=mailo header.b=j+s1h3F5; dkim=pass header.i=@mailgun.org header.s=mg header.b=L2fiHnCn; spf=pass (google.com: domain of bounce+a6cce7.4d1858-tjphuhs=gmail.com@mg2.substack.com designates 161.38.201.183 as permitted sender) smtp.mailfrom="bounce+a6cce7.4d1858-tjphuhs=gmail.com@mg2.substack.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=substack.com DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mg2.substack.com; q=dns/txt; s=mailo; t=1774454142; x=1774461342; h=List-Unsubscribe-Post: List-Unsubscribe: List-Post: List-Id: List-Archive: List-Owner: Reply-To: In-Reply-To: References: Sender: Sender: Date: Message-Id: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: X-Feedback-Id; bh=qNEgRmigRbz4VRYpf4dnZkeJfIF14ZBEw3GW25uocU8=; b=j+s1h3F5HYjfiNOPgpEoawm3Wo2ptDUc/BwMzPi5IHQy/AwTL34U9GqQQDpWVm2lND3lNVL8UY97ytRFGc0JTI8WxAOEHGP40AJJ5LWomSKC4FPThTIdv/r0c9Qn537lNvbjP/BSGN5Zy5/hpjTXfGWjD4o8mNNuoiwrVxrWB2s= DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mailgun.org; q=dns/txt; s=mg; t=1774454142; x=1774461342; h=List-Unsubscribe-Post: List-Unsubscribe: List-Post: List-Id: List-Archive: List-Owner: Reply-To: In-Reply-To: References: Sender: Sender: Date: Message-Id: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: X-Feedback-Id; bh=qNEgRmigRbz4VRYpf4dnZkeJfIF14ZBEw3GW25uocU8=; b=L2fiHnCng3qxVpGoC8l5KtDpepkIo1CbYWVEKDlDXtcrr9chpXfa2+QWOAjqnwhTImCBhaokgfpHWHigpGHlul1mafJN3qHrvJOrTJBHLd71Kv3+DX2eTMiDTQkrzsscgjgm+ncSXfNuTFYxUdXk51wa85HHNR7Su8+HPAP/bDc= X-Mailgun-Sid: WyIxODZiYSIsInRqcGh1aHNAZ21haWwuY29tIiwiNGQxODU4Il0= X-Feedback-Id: postmaster@mg2.substack.com:post:5a78b6d5cd16820001f2a9d4:mailgun Received: by 21e8fdf91f7f43a170f46803c5c6a6329b5f4e0853df352b4de88fdf5a7f0446 with HTTP id 69c4057db2c138bc4a02c876; Wed, 25 Mar 2026 15:55:41 GMT X-Mailgun-Sending-Ip: 161.38.201.183 Mime-Version: 1.0 Content-Type: multipart/alternative; boundary="be792e3b0abe1ebbf9036419af07d003543528cdd5b77ba5cd5cca2230b7" Subject: PNC-27: The Research Peptide That Targets Cancer Cells Directly From: Derek from Peptide Price To: tjphuhs@gmail.com X-Mailgun-Tag: post X-Mailgun-Track-Clicks: false Message-Id: <20260325155526.3.44aa07d343b1044d@mg2.substack.com> Date: Wed, 25 Mar 2026 15:55:26 +0000 Feedback-Id: post-192109320:cat-post:pub-3365367:substack Sender: Derek from Peptide Price References: In-Reply-To: Reply-To: Derek from Peptide Price List-Owner: List-Url: List-Archive: List-Id: List-Post: List-Unsubscribe: List-Unsubscribe-Post: List-Unsubscribe=One-Click X-Mailgun-Variables: {"category": "post", "email_generated_at": "1774454141577", "is_freemail": "true", "post_audience": "everyone", "post_id": "192109320", "post_type": "newsletter", "pub_community_enabled": "true", "publication_id": "3365367", "subdomain": "derekpruski", "user_id": "273622398"} --be792e3b0abe1ebbf9036419af07d003543528cdd5b77ba5cd5cca2230b7 Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: quoted-printable View this post on the web at https://derekpruski.substack.com/p/pnc-27-the-= research-peptide-that If you=E2=80=99ve never heard of PNC-27, you=E2=80=99re not alone =E2=80=94= it=E2=80=99s one of the more unique compounds being studied in the researc= h space, and the mechanism is unlike almost anything else in the peptide wo= rld. Let me break it down from the ground up so it actually makes sense. All compounds referenced in this post are for research use only, not for hu= man consumption. What Is PNC-27? PNC-27 is a synthetic research peptide that was developed with a very speci= fic goal: to selectively target and destroy cancer cells while leaving heal= thy cells alone. That=E2=80=99s a bold thing to say, so let=E2=80=99s walk through exactly h= ow the research suggests it does that =E2=80=94 because the mechanism is ac= tually fascinating once you understand what=E2=80=99s happening. The Two-Part Design PNC-27 is essentially a two-part peptide. Each part has a distinct job, and= they work together in sequence. Part One: The Targeting System The first part of PNC-27 is derived from a protein your body already makes = called p53. p53 is one of the most important proteins in the human body. Its job is to = act as a tumor suppressor =E2=80=94 essentially a quality control checkpoin= t that monitors cells for damage or abnormal behavior. When a cell starts b= ehaving incorrectly, p53 steps in and triggers a process called apoptosis, = which is just a technical word for programmed cell death. Think of it like = p53 hitting a self-destruct button on a damaged or dangerous cell before it= can become a problem. Now here=E2=80=99s where it gets interesting. Cancer cells have figured out= how to disable p53. One of the primary ways they do this is through a prot= ein called MDM2 (sometimes called HDM2 in humans). MDM2 essentially grabs o= nto p53 and prevents it from doing its job =E2=80=94 it=E2=80=99s like putt= ing a lock on the self-destruct button so the cancer cell can keep dividing= unchecked. The first part of PNC-27 is designed to mimic the exact region of p53 that = MDM2 binds to. In research, this allows PNC-27 to recognize and bind to MDM= 2 directly =E2=80=94 essentially using the cancer cell=E2=80=99s own defens= e mechanism as a homing signal. In plain terms: cancer cells overexpress MDM2, and PNC-27 uses that as a GP= S to find them. Part Two: The Disruptor Once PNC-27 has located and engaged its target, the second part of the pept= ide goes to work. This portion is what researchers call a membrane-active domain. Its job is = to interact with and disrupt the cell membrane =E2=80=94 the outer wall of = the cell. Here=E2=80=99s why this matters: cancer cell membranes have a different com= position than healthy cell membranes. They carry different electrical charg= es and structural properties that make them more susceptible to this kind o= f disruption. In research models, once PNC-27 binds to MDM2 on the cancer c= ell surface, the membrane-active domain inserts itself into the membrane an= d creates pores =E2=80=94 essentially punching holes in the outer wall of t= he cancer cell. When a cell=E2=80=99s membrane is compromised like this, it can no longer m= aintain its internal environment. The cell loses structural integrity and d= ies. Think of it like this: Part One is the key that finds the right lock. Part = Two is what kicks the door down once it=E2=80=99s found. Why Is This Significant in Research? Most conventional approaches to targeting cancer cells are not selective = =E2=80=94 they affect rapidly dividing cells broadly, which is why there ar= e so many difficult side effects associated with them. The collateral damag= e to healthy tissue is a major research challenge. PNC-27=E2=80=99s proposed mechanism is significant because it relies on a m= arker =E2=80=94 MDM2 overexpression =E2=80=94 that is far more prevalent in= cancer cells than in healthy ones. In research models, healthy cells with = normal MDM2 levels have shown far less susceptibility to PNC-27=E2=80=99s m= embrane disruption effect. This selectivity is what makes it an interesting area of ongoing research. What Does the Research Actually Show? Research on PNC-27 has demonstrated activity against multiple cancer cell l= ines in laboratory settings, including pancreatic, breast, and leukemia cel= l lines. In these studies, PNC-27 has shown the ability to induce membrane = disruption and cell death selectively in cancer cells while leaving non-can= cerous cells largely intact. It is important to note that the bulk of this research has been conducted i= n cell cultures and early animal models. PNC-27 is still in research stages= , and conclusions about efficacy or application cannot be drawn beyond what= controlled research settings have produced. The Takeaway for Beginner Researchers PNC-27 is one of the more conceptually elegant compounds in the research sp= ace. Rather than broadly attacking any fast-dividing cell, it uses a two-st= ep mechanism: find cancer cells by their own defense protein, then exploit = the structural vulnerability of their membrane to induce cell death. The research is early but genuinely interesting, and it represents a broade= r direction in peptide research toward compounds that are highly targeted r= ather than broadly acting. As always =E2=80=94 research use only, not for human consumption. If this i= s an area you=E2=80=99re exploring, make sure you=E2=80=99re sourcing from = vendors with current, verified COAs and third-party testing. Unsubscribe https://substack.com/redirect/2/eyJlIjoiaHR0cHM6Ly9kZXJla3BydXN= raS5zdWJzdGFjay5jb20vYWN0aW9uL2Rpc2FibGVfZW1haWw_dG9rZW49ZXlKMWMyVnlYMmxrSW= pveU56TTJNakl6T1Rnc0luQnZjM1JmYVdRaU9qRTVNakV3T1RNeU1Dd2lhV0YwSWpveE56YzBOR= FUwTVRReExDSmxlSEFpT2pFNE1EVTVPVEF4TkRFc0ltbHpjeUk2SW5CMVlpMHpNelkxTXpZM0lp= d2ljM1ZpSWpvaVpHbHpZV0pzWlY5bGJXRnBiQ0o5LkYwU0gyaWVxZ2hjbXpnYUxtRmxIODYxR0d= JeHEyN0dybDdpTVdGZC00U1UiLCJwIjoxOTIxMDkzMjAsInMiOjMzNjUzNjcsImYiOnRydWUsIn= UiOjI3MzYyMjM5OCwiaWF0IjoxNzc0NDU0MTQxLCJleHAiOjIwOTAwMzAxNDEsImlzcyI6InB1Y= i0wIiwic3ViIjoibGluay1yZWRpcmVjdCJ9.a7szs1Nx54V_pyE1J_VEMfGqdP4CHbhn8o2eXXC= oUFA? --be792e3b0abe1ebbf9036419af07d003543528cdd5b77ba5cd5cca2230b7 Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable PNC-27: The Research Pep= tide That Targets Cancer Cells Directly3D""
If you’ve never heard of PNC-27, you’re not alone — = it’s one of the more unique compounds being studied in the research s= pace, and the mechanism is unlike almost anything else in the peptide world= =2E
͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­
Forwarded this email? Subscribe here for more

PNC-27: The Research Peptide That Ta= rgets Cancer Cells Directly

Derek
=
 
3D""
<= table role=3D"presentation" width=3D"38" border=3D"0" cellspacing=3D"0" cel= lpadding=3D"0">
3D""=
3D""
<= /td>=
3D""
READ IN APP3D""
 

If you’ve never heard = of PNC-27, you’re not alone — it’s one of the more unique= compounds being studied in the research space, and the mechanism is unlike= almost anything else in the peptide world. Let me break it down from the g= round up so it actually makes sense.

All compounds referenc= ed in this post are for research use only, not for human consumption.

<= /tbody>
3D""

What Is PNC-27?

PNC-27 is a synthetic research peptide that was developed wi= th a very specific goal: to selectively target and destroy cancer cells whi= le leaving healthy cells alone.

That’s a bold thing t= o say, so let’s walk through exactly how the research suggests it doe= s that — because the mechanism is actually fascinating once you under= stand what’s happening.

The Two-Part Design

PNC-27 is essentially a two-part peptide. Each part h= as a distinct job, and they work together in sequence.

Part One: The Targeting System

The first part = of PNC-27 is derived from a protein your body already makes called p53.

=

p53 is one of the most important proteins in the human body. I= ts job is to act as a tumor suppressor — essentially a quality contro= l checkpoint that monitors cells for damage or abnormal behavior. When a ce= ll starts behaving incorrectly, p53 steps in and triggers a process called = apoptosis, which is just a technical word for programmed cell death. Think = of it like p53 hitting a self-destruct button on a damaged or dangerous cel= l before it can become a problem.

Now here’s where it= gets interesting. Cancer cells have figured out how to disable p53. One of= the primary ways they do this is through a protein called MDM2 (sometimes = called HDM2 in humans). MDM2 essentially grabs onto p53 and prevents it fro= m doing its job — it’s like putting a lock on the self-destruct= button so the cancer cell can keep dividing unchecked.

The= first part of PNC-27 is designed to mimic the exact region of p53 that MDM= 2 binds to. In research, this allows PNC-27 to recognize and bind to MDM2 d= irectly — essentially using the cancer cell’s own defense mecha= nism as a homing signal.

In plain terms: cancer cells overe= xpress MDM2, and PNC-27 uses that as a GPS to find them.

Part Two: The Disruptor

Once PNC-27 has loca= ted and engaged its target, the second part of the peptide goes to work.

This portion is what researchers call a membrane-active domai= n. Its job is to interact with and disrupt the cell membrane — the ou= ter wall of the cell.

Here’s why this matters: cancer= cell membranes have a different composition than healthy cell membranes. T= hey carry different electrical charges and structural properties that make = them more susceptible to this kind of disruption. In research models, once = PNC-27 binds to MDM2 on the cancer cell surface, the membrane-active domain= inserts itself into the membrane and creates pores — essentially pun= ching holes in the outer wall of the cancer cell.

When a ce= ll’s membrane is compromised like this, it can no longer maintain its= internal environment. The cell loses structural integrity and dies.

Think of it like this: Part One is the key that finds the right l= ock. Part Two is what kicks the door down once it’s found.

Why Is This Significant in Research?

= Most conventional approaches to targeting cancer cells are not selective &#= 8212; they affect rapidly dividing cells broadly, which is why there are so= many difficult side effects associated with them. The collateral damage to= healthy tissue is a major research challenge.

PNC-27’= ;s proposed mechanism is significant because it relies on a marker — = MDM2 overexpression — that is far more prevalent in cancer cells than= in healthy ones. In research models, healthy cells with normal MDM2 levels= have shown far less susceptibility to PNC-27’s membrane disruption e= ffect.

This selectivity is what makes it an interesting are= a of ongoing research.

What Does the Research Actuall= y Show?

Research on PNC-27 has demonstrated activi= ty against multiple cancer cell lines in laboratory settings, including pan= creatic, breast, and leukemia cell lines. In these studies, PNC-27 has show= n the ability to induce membrane disruption and cell death selectively in c= ancer cells while leaving non-cancerous cells largely intact.

It is important to note that the bulk of this research has been conduc= ted in cell cultures and early animal models. PNC-27 is still in research s= tages, and conclusions about efficacy or application cannot be drawn beyond= what controlled research settings have produced.

The= Takeaway for Beginner Researchers

PNC-27 is one o= f the more conceptually elegant compounds in the research space. Rather tha= n broadly attacking any fast-dividing cell, it uses a two-step mechanism: f= ind cancer cells by their own defense protein, then exploit the structural = vulnerability of their membrane to induce cell death.

The r= esearch is early but genuinely interesting, and it represents a broader dir= ection in peptide research toward compounds that are highly targeted rather= than broadly acting.

As always — research use only, = not for human consumption. If this is an area you’re exploring, make = sure you’re sourcing from vendors with current, verified COAs and thi= rd-party testing.

Upgrade to p= aid

You're= currently a free subscriber to upgrade your s= ubscription.

Upgrade to paid

 
=
<= /table>
3D""Share
 
 
=
=
= Like
3D""Comment=
3D"=Resta= ck
 

© 2026 Derek Pruski
548 Market Street PMB 72296, San Francisco, CA 94= 104
Unsubscribe=

3D"Start

3D"" --be792e3b0abe1ebbf9036419af07d003543528cdd5b77ba5cd5cca2230b7--